Africa: Children and HIV - What We Found About Vaccine-Preventable Diseases
[The Conversation Africa] Sub-Saharan African countries account for about a third of the global burden of vaccine-preventable diseases. These diseases are responsible for a large proportion of deaths in children under the age of five.
This report describes the use of spatiotemporal analysis to identify clusters of people with mumps and target public health response efforts in Chicago.
[GFO] On 24 April 2020, the Global Fund, the World Health Organization (WHO) and a range of global health actors launched the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration to speed up the development and production of vaccines, diagnostics, and therapeutics for the coronavirus disease 2019 (COVID-19) for all who need them globally. The other global health actors in the partnership include the Bill&Melinda Gates Foundation (BMGF), the Coalition for Epidemic Preparedness Innovations (CEP
[The Conversation Africa] The World Health Organisation (WHO) recently noted that "researchers are working at break-neck speed" to understand SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). They are also working to develop potential vaccines, medicines and other technologies that are affordable and equitable. By June 2020 - six months since it was first identified - thousands of therapeutic trials and dozens of vaccine development studies were under way, including one vaccine study each in South Africa and Nigeria
[African Arguments] As we are re-learning with the coronavirus pandemic, the outbreak and global spread of a novel disease, which has neither vaccine nor proven cure, causes panic. More precisely, it causes political leaders and communities to resort to behaviours that intensify confusion and anxiety. Meanwhile, despite expert assurances to the contrary, public health 'best practices' are at best well-informed projections with the uncertainty factors on mute. At worst they can be superstitions.
[The Conversation Africa] An HIV vaccine trial that started in 2016 in South Africa was halted in February 2020. The study sponsors made the call after interim results showed that the vaccine, known as HVTN 702, did not prevent HIV. This result was disappointing, but the search for an effective HIV vaccine continues. Anatoli Kamali speaks to The Conversation Africa's Ina Skosana about other developments in the field.
[Nation] When is was announced that the trials of HVTN 70, an experimental vaccine that could protect people against HIV, the virus that causes Aids, had been cancelled for non-efficacy, Ms Inviolata Mmbavi was disappointed.
[UCT] The early abandonment of HIV vaccine study HVTN 702 (also known as Uhambo) in South Africa for failing to prevent infections is a huge setback in the quest to find an HIV vaccine. However, this will not deter scientists, said the University of Cape Town's (UCT) Professor Linda-Gail Bekker.
By Margarite Nathe, Principal Editor/Writer, IntraHealth International ; Lucy Mphuru, Country Director&Project Director, Tohara Plus Project Lucy Mphuru (center left) talks with health workers and clients at an IntraHealth-supported mobile clinic in Shinyanga that provides voluntary male circumcision services. Photo by Trevor Snapp for IntraHealth International.November 26, 2019Lucy Mphuru has a big job.Every day, she and her team at IntraHealth International in Tanzania work with frontline health workers and government partners to improve health services in a country of 58 million—1.6 million of whom live ...
Conclusion: Prevalence of transfusion-transmissible viral infections was higher among hemodialysis patients, especially HCV infection which was an alarming situation and therefore strict adherence to infection control strategies, barrier precautions, and preventive measures, including routine hepatitis B vaccination and regular virological follow-up were recommended along with regular education and training programs of technical and nursing personnel's involved with dialysis patients.
CONCLUSIONS: RC remains a frequent argument against the availability and provision of prevention methods for vulnerable populations. Individuals should be able to benefit from the full panel of BIs options available, to find and adapt methods according to their needs. Current, past and future PrEP users, with other stakeholders, may provide valuable insight into innovative solutions and programmes to control HIV and other STIs. PMID: 31468693 [PubMed - in process]